Acalabrutinib 100mg Tablet

Acalabrutinib 100mg Tablet contains acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor used for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and selected mantle cell lymphoma (MCL) indications depending on the local approval. Generic acalabrutinib contains the same active ingredient as Calquence® 100mg, while manufacturer, excipients and packaging may differ. Current market terminology also includes Calquence 100 mg comprimés pelliculés, Acalabrutinib 100 mg Filmtabletten, 아칼라브루티닙 100mg and акалабрутиниб 100 мг.

Product Information

Generic Name

Acalabrutinib

Strength

100mg

Dosage Form

Tablet

Route

Oral

Drug Class

Bruton Tyrosine Kinase (BTK) Inhibitor

Therapeutic Area

Hematologic Oncology

Reference Brand

Calquence® 100mg

Primary Uses

CLL, SLL, selected MCL indications

Prescription Status

Prescription medicine

Manufacturer

Varies by generic product

Pack Size

Varies by manufacturer and country

Acalabrutinib 100mg for CLL & MCL

Acalabrutinib 100mg is used in approved treatment settings for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and for certain adult mantle cell lymphoma (MCL) indications. U.S., UK, Australian and other national labels differ in the exact treatment setting and combinations allowed.

Why Search for Generic Calquence 100mg?

Acalabrutinib 100mg is the active ingredient in Calquence®. Generic products are marketed by different manufacturers and can have different packaging, inactive ingredients and physical appearance. The exact product should always be matched to the relevant national authorization and prescription requirements.

Availability & Ordering

Searches for Acalabrutinib 100mg Tablet, Calquence 100mg, generic Calquence 100mg, acalabrutinib price, acalabrutinib tablets and acalabrutinib for CLL are relevant to this product category. Supply of prescription oncology medicines should follow the prescribing, pharmacy and import requirements applicable to the destination country.

How it works

Acalabrutinib selectively inhibits BTK, a protein involved in B-cell receptor signaling. Blocking BTK can interfere with signaling that supports the growth and survival of malignant B cells.

Acalabrutinib treatment requires specialist supervision. Important labeled risks include serious infections, bleeding, reduced blood cell counts, cardiac arrhythmias, liver injury and second primary malignancies. Drug interactions, particularly involving CYP3A medicines, also require attention.